RETREATMENT WITH SURFACTANT IN VERY LOW BIRTH WEIGHT PRETERM INFANTS: RISK PREDICTORS AND THEIR INFLUENCE ON NEONATAL OUTCOMES

Overview

Journal Rev Paul Pediatr

Specialty Pediatrics

Date 2020 Nov 18

PMID 33206840

Citations 1

Authors

Walusa Assad Goncalves Ferri

Adriana Carnevale da Silva

Eliana Motta Fernandes Sacramento

Cristina Calixto

Davi Casale Aragon

Jamil Pedro de Siqueira Caldas

Affiliations

Soon will be listed here.

Abstract

Objective: To assess clinical predictors and outcomes associated to the need for surfactant retreatment in preterm infants.

Methods: Retrospective cohort study, including very low birth weight preterm infants from January 2006 to December 2015 who underwent surfactant replacement therapy. Beractant was used (100 mg/kg), repeated every six hours if FiO2 ≥0.40. The subjects were classified into two groups: single surfactant dose; and more than one dose (retreatment). We evaluated maternal and neonatal predictors for the need of retreatment and neonatal outcomes associated to retreatment.

Results: A total of 605 patients (44.5%) received surfactant; 410 (67.8%) one dose, and 195 (32.2%) more than one dose: 163 (83.5%) two doses and 32 (16.4%) three doses. We could not find clinical predictors for surfactant retreatment. Retreatment was associated to a greater chance of BPD in infants >1000 g (RR 1.78; 95%CI 1.30‒2.45) and ≤1000 g (RR 1.33; 95%CI 1.04‒1.70), in infants with gestational age<28 weeks (RR 1.56; 95%CI 1.12‒2.18) and ≥28 weeks (RR 1.50; 95%CI 1.17‒1.92), in neonates with early sepsis (RR 1.48; 95%CI 1.20‒1.81), and in infants not exposed to antenatal corticosteroids (RR 1.62; 95%CI 1.20‒2.17).

Conclusions: We could not find predictor factors associated to surfactant retreatment. The need for two or more doses of surfactant was significantly related to bronchopulmonary dysplasia.

Citing Articles

Clinical predictors for surfactant retreatment in preterm infants with respiratory distress syndrome: the results of a pooled analysis.

Dani C, Poggi C, Agosti M, Bellettato M, Betta P, Biban P Ital J Pediatr. 2025; 51(1):1.

PMID: 39757182 PMC: 11702167. DOI: 10.1186/s13052-024-01828-1.

References

Frerking I, Gunther A, Seeger W, Pison U . Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med. 2002; 27(11):1699-717. DOI: 10.1007/s00134-001-1121-5. View

Fehlmann E, Tapia J, Fernandez R, Bancalari A, Fabres J, DApremont I . [Impact of respiratory distress syndrome in very low birth weight infants: a multicenter South-American study]. Arch Argent Pediatr. 2010; 108(5):393-400. DOI: 10.1590/S0325-00752010000500004. View

Kattwinkel J, Bloom B, Delmore P, Glick C, Brown D, Lopez S . High-versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome. Pediatrics. 2000; 106(2 Pt 1):282-8. DOI: 10.1542/peds.106.2.282. View

Mussavi M, Mirnia K, Asadollahi K . Comparison of the Efficacy of Three Natural Surfactants (Curosurf, Survanta, and Alveofact) in the Treatment of Respiratory Distress Syndrome Among Neonates: A Randomized Controlled Trial. Iran J Pediatr. 2017; 26(5):e5743. PMC: 5297380. DOI: 10.5812/ijp.5743. View

Ramanathan R, Rasmussen M, Gerstmann D, Finer N, Sekar K . A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol. 2004; 21(3):109-19. DOI: 10.1055/s-2004-823779. View

Vento M, Curstedt T, Halliday H, Hallman M, Saugstad O, Speer C . More about surfactant, oxygen, caffeine and chronic lung disease. Neonatology. 2014; 105(4):320-2. DOI: 10.1159/000360653. View

Lim K, Wheeler K, Gale T, Jackson H, Kihlstrand J, Sand C . Oxygen saturation targeting in preterm infants receiving continuous positive airway pressure. J Pediatr. 2014; 164(4):730-736.e1. DOI: 10.1016/j.jpeds.2013.11.072. View

Morley C . Systematic review of prophylactic vs rescue surfactant. Arch Dis Child Fetal Neonatal Ed. 1997; 77(1):F70-4. PMC: 1720672. DOI: 10.1136/fn.77.1.f70. View

Sweet D, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R . European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update. Neonatology. 2016; 111(2):107-125. DOI: 10.1159/000448985. View

10.

Sweet D, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A . European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019; 115(4):432-450. PMC: 6604659. DOI: 10.1159/000499361. View

11.

Soll R, Ozek E . Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2009; (1):CD000141. DOI: 10.1002/14651858.CD000141.pub2. View

12.

Glass H, Costarino A, Stayer S, Brett C, Cladis F, Davis P . Outcomes for extremely premature infants. Anesth Analg. 2015; 120(6):1337-51. PMC: 4438860. DOI: 10.1213/ANE.0000000000000705. View

13.

Papile L, BURSTEIN J, Burstein R, KOFFLER H . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978; 92(4):529-34. DOI: 10.1016/s0022-3476(78)80282-0. View

14.

Walsh M, Kliegman R . Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986; 33(1):179-201. PMC: 7131118. DOI: 10.1016/s0031-3955(16)34975-6. View

15.

Singh N, Halliday H, Stevens T, Suresh G, Soll R, Rojas-Reyes M . Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2015; (12):CD010249. PMC: 9465687. DOI: 10.1002/14651858.CD010249.pub2. View

16.

Jobe A . What is BPD in 2012 and what will BPD become?. Early Hum Dev. 2012; 88 Suppl 2:S27-8. DOI: 10.1016/S0378-3782(12)70009-9. View

17.

Ehrenkranz R, Walsh M, Vohr B, Jobe A, Wright L, Fanaroff A . Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005; 116(6):1353-60. DOI: 10.1542/peds.2005-0249. View

18.

Boix H, Rite S, Arruza L, Fernandez C, Serrano I, Baquedano I . Underdosing of Surfactant for Preterm Babies with Respiratory Distress Syndrome in Clinical Practice: A Retrospective Cohort Study. Am J Perinatol. 2018; 36(9):943-948. DOI: 10.1055/s-0038-1675645. View

19.

Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F . Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics. 1997; 100(1):E4. DOI: 10.1542/peds.100.1.e4. View

20.

Sahni R, Schiaratura M, Polin R . Strategies for the prevention of continuous positive airway pressure failure. Semin Fetal Neonatal Med. 2016; 21(3):196-203. DOI: 10.1016/j.siny.2016.02.008. View